ReviewBMJ open2026
An Open Pharma Vision for company-sponsored biomedical research publications.
Review in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enabling equitable open access to commercially funded research publications.PLoS medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Open Science aims to fight misinformation and improve trust in scientific research; it encourages the reliability and accessibility of evidence, reduces inequalities through the democratisation of scientific knowledge and focuses scientific endeavours on issues of societal significance. As a multisponsor collaboration committed to driving positive change, Open Pharma has a multifaceted vision for scientific research publications funded by pharmaceutical companies ('company research publications') that aligns strongly with Open Science tenets. This new vision statement outlines our forward-looking principles for company research publications, both for short-term attainment ('immediate') and long-term commitment ('ultimate'). Together, the principles provide a framework for positive collective action by all stakeholders involved in the development and dissemination of peer-reviewed company research publications. Underpinned by our central commitment to transparency for company research publications, we outline goals for: universal access to these publications; provision of peer-reviewed plain language summaries of the publications to aid comprehension among non-specialist readers; leveraging author and institutional metadata to advance transparency, discoverability and research impact; working towards FAIR (Findability, Accessibility, Interoperability, and Reuse) data principles through cross-sector consensus and action, and disclosure of patient involvement in research and its reporting to support transparency and encourage a research ecosystem attuned to patient centricity. We call on all stakeholders to realise the Open Pharma Vision and achieve an open and trusted future for company research publications that will ultimately advance patient care and improve global health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.